Previous 10 | Next 10 |
Alnylam Pharmaceuticals ( NASDAQ: ALNY ) on Thursday said lead independent director Amy Schulman will assume the role of chair of the board from Michael Bonney. Bonney will continue on the board as a non-independent director. Bonney had been serving an interim role ...
– Appoints Carolyn Bertozzi, Ph.D., Nobel Laureate and Leading Voice for Chemical Biology, Emerging Technology, and Life Sciences Companies – – Michael W. Bonney Steps Down as Executive Chair and Continues on Board as Non-Independent Director – ...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview and participate in a Q&A session at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 9:45 am PT (12:45 pm ...
Alnylam Pharma ( NASDAQ: ALNY ) said on Wednesday it had submitted an application to begin trial of ALN-KHK, an investigational RNAi therapy targeting ketohexokinase to treat Type 2 diabetes mellitus (T2DM) to Health Canada. The company plans to begin enrollment in a Phase 1/...
– Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Comp...
− Product and Pipeline Goals Detail Execution across Four Commercial Brands, Including One Potential Label Expansion, and Ten Clinical Data Readouts From Proprietary and Partner Programs – − Pipeline Programs and Scientific Innovation Highlighted at R&D Day Ex...
– sNDA Submission is Based on Findings from the APOLLO-B Phase 3 Study That Showed Patisiran Demonstrated Significant Improvement on Functional Capacity, Health Status and Quality of Life Compared to Placebo at Month 12 – – Study Also Demonstrated Encouraging Safety P...
- Recognition Marks Alnylam’s Eighth Year in a Row on this Prestigious List, and the Second Consecutive Year Ranking #1 - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2022 ...
Summary Recent clinical successes and M&A could bring interest back to biotechnology, especially among mid-capitalization names with derisked or approved products. Restructuring, corporate activity, and COVID-19 revenues have significantly improved the funding positions of man...
Summary Alnylam's third quarter results were basically on target, with a stronger Amvuttra launch leading to more Onpattro switchovers, and some weakness in Givlaari and Oxlumo. There are still multiple credible and significant questions about whether Onpattro data will support wi...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...